secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001485003-23-000014
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma appoints prominent oncologist to SAB; merger on track for Q1 2023
-------------------------------------------------------------------------

- Padmanee Sharma, MD, PhD, from MD Anderson, appointed to Carisma's Scientific Advisory Board.
- She brings expertise in immuno-oncology for CAR-M and checkpoint inhibitor combination trials.
- Merger with Sesen Bio expected to close in Q1 2023, subject to stockholder approval and conditions.
- Phase 1 trial of CT-0508 + Keytruda actively recruiting; first patient anticipated by end of Q1 2023.
- Merger agreement amended Dec 29, 2022 to deliver greater value to Sesen Bio stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000014/0001485003-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000014/sesn-20230131.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer